AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00813124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion on day 0 administered by vein after collected from donor.
Study NCT03262272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIE A Hemodialyzer
Description: polysulfon membrane coated with vitamin E
Study NCT03262272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rexsys 27H hemodialyzer
Description: polyethersulfon membrane with large surface area : 2,7m²
Study NCT03262272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leoceed 21HX hemodialyzer
Description: polyslfon membrane with gamma sterilization
Study NCT03262272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polypure 22S+ hemodialyzer
Description: polysulfon membrane with steam sterilization
Study NCT00733824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Study NCT00733824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT00733824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Study NCT04929561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-conferencing group
Description: No intervention
Study NCT01248117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 2.0mg
Description: Monthly, intravitreal injection 0.05ml
Study NCT02538926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM or IV
Study NCT02538926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02538926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02538926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02538926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study NCT02538926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02538926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02538926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01548573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02538926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02168166 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Executive Function Training
Study NCT02168166 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo version of executive function training
Study NCT05267067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory exercises
Description: Manual respiratory exercises versus respiratory exercises with pressure meter
Study NCT02035007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCCO Catheter (Pulsiocath 5F)
Description: Measuring of PiCCO derived values
Study NCT03198273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pilates exercises
Description: servical, lumbal, pelvic muscles
Study NCT03198273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy program
Description: hot-pack will apply for 20 minutes. Convansionel TENS will apply on the lumbar regions of the cases of the control group paravertebrally with
Study NCT00260234 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Cultured Islet Cells (human); Encapsulated
Study NCT01374113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg safinamide
Description: 50 mg safinamide on Day 1
Study NCT00410696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: 5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
Study NCT00410696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg/day sc at day +1
Study NCT01228240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01228240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT00881075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SeeMore(TM)
Description: single dose intravenous injectable
Study NCT01548573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT01548573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given PO
Study NCT01548573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT02050373 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Level laser
Description: Application of laser therapy in low power mucosa jugal right and left upper and lower labial mucosa, floor of the mouth, tongue side of the right and left and belly of the tongue.
Study NCT00978640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fast and exercise
Description: fasting 36 h and exercise 1 h 50% VO2max
Study NCT00978640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise 1 h 50% VO2max
Study NCT01570127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized Acupuncture
Description: The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
Study NCT01570127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized Acupuncture
Description: The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
Study NCT01570127 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.
Study NCT01570127 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Waiting
Description: No interventions were applied to the patients in this group.
Study NCT02237066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chocolate PTA Balloon Angioplasty
Description: OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
Study NCT02237066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA Balloon Angioplasty
Description: OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
Study NCT03508466 — intervention group
Intervention type: BEHAVIORAL
Intervention: hypersensitivity reaction
Description: Previous hypersensitivity reaction
Study NCT03716440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature exposure
Description: Participants will view images of nature.
Study NCT03716440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-nature exposure
Description: Participants will view non-nature images.
Study NCT01807910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl-D9-choline
Description: Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
Study NCT01807910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl-D9-choline
Description: Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
Study NCT04332874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolated Limb Infusion
Description: ILI will be performed within 18 days of initiation of pembrolizumab. ILI (infusion of melphalan and dactinomycin into the affected limb via arterial catheter) will be performed in the interventional radiology suite under anesthesia. In pediatric patients, the pediatric pharmacist w ill be consulted prior to the procedure, and an appropriate prophylactic anti-emetic therapy and dose will be selected for the individual patient.
Study NCT04332874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at a dose of 200 mg will be administered intravenously on Day 1 and every 3 weeks(+/= 3 days) thereafter. In adolescent patients, the dosing of pembrolizumab w ill be 2 mg/kg up to a maximum of 200 mg.
Study NCT04332874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion of melphalan and dactinomycin
Description: infusion of melphalan and dactinomycin
Study NCT03092115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIV medication adherence app
Description: A medication adherence mobile application for HIV+ youth. It is a theory-driven, patient-centered, mobile phone-based intervention targeting medication adherence and engagement in care among HIV+ youth with features including, but not limited to: custom avatar, medication reminders, calendar tracking of medication adherence, and anonymous chat function for social support.
Study NCT01626209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
Study NCT03469882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein nutrition
Description: Patients in the HPE group will be submitted to nutritional support preferably through the enteral route. Energy expenditure will be determined by indirect calorimetry. They will receive 2.0 to 2.2 grams/kg/day of protein.
Study NCT03469882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycle ergometry exercise
Description: Patients will be submitted to two daily sessions of exercise (cycle ergometry) 15 minutes duration each, during the 7 days of the week. The intervention will be maintained exclusively duting the patient's stay in the ICU. The cycle ergometer will be the MotoMed Letto II (Reck Technik, Germany).
Study NCT03469882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care group
Description: Participants randomized to the usual care group will receive usual care protein and exercise.
Study NCT03144115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT03144115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT02512991 — intervention group
Intervention type: OTHER
Intervention: Helicopter Emergency Medical Service
Description: May 1st 2010, the first Danish Helicopter Emergency Medical System (HEMS) was implemented in Region Zealand and the Capital Region of Denmark.
Study NCT03853980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Contouring System
Description: Single treatment of skin resection (removal of loose skin)
Study NCT00381667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M
Description: M salt
Study NCT00381667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444H
Description: H salt
Study NCT00381667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT01411475 — intervention group
Intervention type: OTHER
Intervention: Bifurcation restenosis classification
Description: Classification of restenosis involving coronary bifurcation according to their pattern
Study NCT03922321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1401
Description: RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
Study NCT00155311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthodontic treatment
Study NCT02052024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
Study NCT02052024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYOBLOC
Description: Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
Study NCT03154541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synrinse
Description: Non-CF Cohort The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~CF Cohort The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
Study NCT00015964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Study NCT02522689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Ultra-mini PCNL will be performed.
Study NCT01816334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Study NCT01816334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen
Study NCT02522689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Micro PCNL will be performed.
Study NCT01816334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Study NCT01816334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Study NCT02765139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engaging Men through Accountable Practice
Description: Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.
Study NCT02765139 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alternative intervention
Description: Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
Study NCT03840031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fe OFSP meal labelled with Fe-58
Description: 400 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
Study NCT03840031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control OFSP meal labelled with Fe-57
Description: 400 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
Study NCT03544567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
Study NCT03136978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of M1 and M2 macrophages by flow cytometry.
Description: To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
Study NCT01807780 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biological monitoring
Study NCT03830489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol
Description: The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet
Study NCT03830489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol plus ascorbic acid
Description: The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet
Study NCT01589458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste
Description: 1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
Study NCT01589458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste
Description: 1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
Study NCT02656303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab IV infusion
Study NCT02656303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib tablets
Study NCT02342574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Administration of active compound
Study NCT03097068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: 0.3mg Lucentis
Study NCT01714700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High protein diet, Resistance exercise
Description: The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
Study NCT01714700 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: High protein diet, Resistance exercise
Description: The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
Study NCT01714700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet, Resistance exercise
Description: The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)